调节性T细胞治疗克罗恩病:挑战与进展
综述指出,尽管治疗靶点增多,仍有相当比例炎症性肠病患者长期患病;小鼠和人体研究显示调节性T细胞在免疫稳态中起关键作用,克罗恩病患者存在调节性T细胞数量和抑制功能缺陷。文章回顾其功能与诱导肠道黏膜免疫耐受的途径,探讨细胞疗法制造原则与挑战,并讨论迄今临床试验证据,重点为克罗恩病调节性T细胞疗法的开发。
要点
- 克罗恩病患者存在调节性T细胞数量和抑制功能缺陷
- 调节性T细胞在肠道黏膜免疫耐受中起关键作用
- 调节性T细胞疗法的制造与临床转化仍面临挑战
核心结论
- 调节性T细胞数量和抑制功能缺陷与克罗恩病免疫失衡相关,细胞疗法开发是当前方向。
研究设计与样本
- 综述,总结调节性T细胞功能、肠道黏膜免疫耐受途径、细胞疗法制造原则与挑战及临床试验证据。
主要发现
- 小鼠和人体研究显示调节性T细胞在免疫稳态中起关键作用。
- 克罗恩病患者存在调节性T细胞数量和抑制功能缺陷。
临床怎么用
- 关注调节性T细胞疗法在克罗恩病中的临床试验安全性和有效性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.
引用
- Clough JN, Omer OS, Tasker S, et al. Regulatory T-cell therapy in Crohn's disease: challenges and advances. Gut. 2020. PMID: 31980447. doi:10.1136/gutjnl-2019-319850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。